
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About
Sol Gel Technologies Ltd (SLGL)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SLGL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $4
1 Year Target Price $4
0 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.18% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 43.01M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 1.22 | 52 Weeks Range 4.01 - 16.89 | Updated Date 08/15/2025 |
52 Weeks Range 4.01 - 16.89 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.67 | Actual - |
Profitability
Profit Margin -107.78% | Operating Margin (TTM) -879.63% |
Management Effectiveness
Return on Assets (TTM) -26.82% | Return on Equity (TTM) -49.39% |
Valuation
Trailing PE - | Forward PE 9.34 | Enterprise Value 27289165 | Price to Sales(TTM) 3.55 |
Enterprise Value 27289165 | Price to Sales(TTM) 3.55 | ||
Enterprise Value to Revenue 2.25 | Enterprise Value to EBITDA 0.24 | Shares Outstanding 2785760 | Shares Floating 689337 |
Shares Outstanding 2785760 | Shares Floating 689337 | ||
Percent Insiders 70 | Percent Institutions 15.75 |
Upturn AI SWOT
Sol Gel Technologies Ltd
Company Overview
History and Background
Sol Gel Technologies Ltd. was founded in 1997 in Israel and went public on the Nasdaq in 2018. They specialize in developing and manufacturing microencapsulated active ingredients for use in various skincare and pharmaceutical products.
Core Business Areas
- Dermatology: Development and commercialization of topical generic and branded dermatology products.
- Active Ingredient Encapsulation: Developing and supplying microencapsulated active ingredients for cosmetic and pharmaceutical applications.
Leadership and Structure
Dr. Alon Seri-Levy serves as the Chief Executive Officer. The company has a Board of Directors and operates with a functional organizational structure based on research, development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- EPSOLAYu00ae: A proprietary microencapsulated benzoyl peroxide (BPO) cream for the treatment of papulopustular rosacea. Market share is growing but still relatively small, competing with brands like Metrogel and Finacea. Revenue estimates not available, but important for growth and expansion.
- ZELSUVMIu00ae: A topical antifungal medication using their encapsulation technology. Further expanding and diversifying their product portfolio. Competitors are generic antifungals such as terbinafine and ketoconazole. Revenue estimates not available, but strategically vital.
- Generic Products: Sol-Gel produces generic dermatology products. Revenue estimates not available.
Market Dynamics
Industry Overview
The dermatology market is growing, driven by increasing awareness of skin conditions and an aging population. The generic dermatology market is highly competitive with pressures on price and margin.
Positioning
Sol Gel Technologies positions itself as an innovator in the dermatology field, particularly through their microencapsulation technology. Their competitive advantage lies in formulating difficult-to-deliver active ingredients into stable and effective products.
Total Addressable Market (TAM)
The global dermatology market is estimated to be in the tens of billions of dollars. Sol Gel is positioning itself to target key market segments within dermatology
Upturn SWOT Analysis
Strengths
- Proprietary microencapsulation technology
- Focus on dermatology
- Approved products with revenue potential
- Experienced management team
Weaknesses
- Limited product portfolio
- Dependence on key products
- Relatively small size compared to competitors
- History of operating losses and dependence on financing
Opportunities
- Expanding product pipeline
- Partnering with larger pharmaceutical companies
- Geographic expansion
- Potential acquisitions to broaden portfolio
Threats
- Competition from established dermatology companies
- Regulatory hurdles
- Patent expirations
- Generic competition
- Unsuccessful clinical trials or regulatory review
Competitors and Market Share
Key Competitors
- VRX
- PRGO
- ALNY
Competitive Landscape
Sol Gel Technologies is a smaller player in a highly competitive market. They compete on innovation and specialized dermatology products. Competitor advantages include wider product portfolios and established distribution networks.
Major Acquisitions
No Acquisitions
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Revenue growth has been limited prior to recent product launches. Dependent on key product and market performance.
Future Projections: Analyst estimates are unavailable. Future growth is expected to depend heavily on successful commercialization and product pipeline expansion.
Recent Initiatives: Recent initiatives include the launch of EPSOLAY and ZELSUVMI, focusing on increasing sales and awareness of these products, and further expanding the product portfolio.
Summary
Sol Gel Technologies is a small-cap dermatology company with innovative microencapsulation technology and several approved products. However, it is currently unprofitable and faces intense competition. Success hinges on EPSOLAY and ZELSUVMI's performance, pipeline expansion, and managing its cash burn. There are further catalysts for future expansion and overall growth if operations can continue with revenues balancing spending.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Earnings reports
- Analyst reports
- Third Party Financials
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Financial data is based on publicly available information and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sol Gel Technologies Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-01-23 | CEO & Executive Chairman Mr. Moshe Arkin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 34 | Website https://www.sol-gel.com |
Full time employees 34 | Website https://www.sol-gel.com |
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.